Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial by Mora, Jesús S. et al.
RESEARCH ARTICLE
Masitinib as an add-on therapy to riluzole in patients with
amyotrophic lateral sclerosis: a randomized clinical trial
JESUS S. MORA1, ANGELA GENGE2, ADRIANO CHIO3 , CONRADO J. ESTOL4,
DELIA CHAVERRI5, MARIA HERNÁNDEZ5, SAÚL MARÍN5, JAVIER MASCIAS5,
GABRIEL E. RODRIGUEZ6, MONICA POVEDANO7, ANDRÉS PAIPA7, RAUL
DOMINGUEZ7, JOSEP GAMEZ8 , MARIA SALVADO8, CHRISTIAN LUNETTA9,
CARLOS BALLARIO10, NILO RIVA11, JESSICA MANDRIOLI12, ALAIN MOUSSY13,
JEAN-PIERRE KINET13,14, CHRISTIAN AUCLAIR13,15, PATRICE DUBREUIL13,16,
VINCENT ARNOLD13, COLIN D. MANSFIELD13, OLIVIER HERMINE13,17 AND ON
BEHALF OF THE AB10015 STUDY GROUP
1ALS Unit, Hospital San Rafael, Madrid, Spain; 2Department of Neurology and Neurosurgery, Montreal
Neurological Institute and Hospital, McGill University, Montreal, Canada; 3Department of Neuroscience,
University of Turin, Turin, Italy; 4Neurological Center for Treatment and Rehabilitation, Buenos Aires,
Argentina; 5Department of Neurology, ALS Unit, Hospital Carlos III, Madrid, Spain; 6Neurology Department,
Neuron Motor Disease Clinic, Hospital JM Ramos, Buenos Aires, Argentina; 7Neurology Department, Bellvitge
Hospital-IDIBELL, Barcelona, Spain; 8Neurology Department, Vall d’Hebron University Hospital, Vall d’Hebron
Research Institute, Autonomous University of Barcelona, Barcelona, Spain; 9NEMO Clinical Centre, Serena
Onlus Foundation, Milan, Italy; 10Neurorosario, Rosario, Argentina; 11Department of Neurology-INSPE, San
Raffaele Scientific Institute, Milan, Italy; 12Department of Neurosciences, St. Agostino-Estense Hospital, Azienda
Ospedaliero Universitaria di Modena, Modena, Italy; 13AB Science, Paris, France; 14Department of Pathology,
Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA; 15Department of Biology,
Universite Paris Sud Universite Paris-Saclay CNRS UMR 8113, Ecole Normale Superieure de Cachan, Cachan,
France; 16INSERM, CNRS, Institut Paoli-Calmettes, CRCM, Centre de Reference des Mastocytoses, Equipe
Labelisee Ligue Nationale Contre le Cancer, Aix-Marseille University, Marseille, France; and 17Imagine Institute,
INSERM UMR 1163 and CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms of
Hemathological Disorders and Therapeutic Implication, Hôpital Necker, Paris, France
Abstract
Objective: To assess masitinib in the treatment of ALS. Methods: Double-blind study, randomly assigning 394 patients
(1:1:1) to receive riluzole (100mg/d) plus placebo or masitinib at 4.5 or 3.0mg/kg/d. Following a blinded transition
from phase 2 to phase 2/3, a prospectively defined two-tiered design was implemented based on ALSFRS-R progression
rate from disease-onset to baseline (DFS). This approach selects a more homogeneous primary efficacy population
(“Normal Progressors”, DFS < 1.1 points/month) while concurrently permitting secondary assessment of the broader
population. Primary endpoint was decline in ALSFRS-R at week-48 (DALSFRS-R), with the high-dose “Normal
Progressor” cohort being the prospectively declared primary efficacy population. Missing data were imputed via last
observation carried forward (LOCF) methodology with sensitivity analyses performed to test robustness. Results: For the
primary efficacy population, masitinib (n¼99) showed significant benefit over placebo (n¼ 102) with a DALSFRS-R
between-group difference (DLSM) of 3.4 (95% CI 0.65–6.13; p¼ 0.016), corresponding to a 27% slowing in rate of
functional decline (LOCF methodology). Sensitivity analyses were all convergent, including the conservative multiple
imputation technique of FCS-REGPMM with a DLSM of 3.4 (95% CI 0.53–6.33; p¼ 0.020). Secondary endpoints
(ALSAQ-40, FVC, and time-to-event analysis) were also significant. Conversely, no significant treatment-effect
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according to DALSFRS-R was seen for the broader “Normal and Fast Progressor” masitinib 4.5mg/kg/d cohort, or
either of the low-dose (masitinib 3.0mg/kg/d) cohorts. Rates of treatment-emergent adverse events (AEs) (regardless of
causality or post-onset DFS) were 88% with masitinib 4.5mg/kg/d, 85% with 3.0mg/kg/d, and 79% with placebo.
Likewise, rates of serious AE were 31, 23, and 18%, respectively. No distinct event contributed to the higher rate
observed for masitinib and no deaths were related to masitinib. Conclusions: Results show that masitinib at 4.5mg/kg/d
can benefit patients with ALS. A confirmatory phase 3 study will be initiated to substantiate these data.
Keywords: Clinical trials, therapy, tyrosine kinase inhibitor, masitinib
Introduction
Amyotrophic lateral sclerosis (ALS) is character-
ized by the progressive loss of motor neurons in
the brain and spinal cord leading to a deterioration
of muscle strength with subsequent wasting, par-
alysis, and loss of motor functions such as speech,
swallowing, and breathing. Respiratory failure usu-
ally leads to death about 4 years after onset,
although life expectancy is highly variable suggest-
ing heterogeneity in the physiopathology of motor
neuron loss (1,2). Worldwide prevalence of ALS is
currently estimated at 235,000 with a projected
69% increase by the year 2040 (1). Despite signifi-
cant effort, the overwhelming majority of clinical
trials have failed to demonstrate efficacy, highlight-
ing an urgent unmet medical need (3,4). Riluzole,
a glutamate antagonist, is the only widely available
disease modifying drug for ALS patients, although
its benefits are a very modest increase in survival,
with no improvement in quality-of-life or slowing
of functional loss. Intravenous edaravone, a free
radical scavenger, recently received approval by the
US Food and Drug Administration (5,6).
Masitinib, an oral tyrosine kinase inhibitor, has
demonstrated promising preclinical activity in ALS
(SOD1G93A) rat models, exerting neuroprotection
via its immunomodulatory properties and in par-
ticular through targeting microglia, macrophage
and mast cell activity, in both central and periph-
eral nervous systems (7–9). Here, we report find-
ings from study AB10015, evaluating the efficacy
and safety of masitinib in ALS patients.
Methods
Study design and oversight
Study AB10015 was an international, multicenter,
phase 2/3, randomized, double-blind, placebo-
controlled trial over a 48-week treatment period. It
commenced in April 2013 and was completed in
December 2016. Patients were randomly assigned
(1:1:1) to receive riluzole (100mg/d) plus placebo
or masitinib at 4.5 or 3.0mg/kg/d (bis in die), with
the high-dose cohort being predefined for primary
analysis. Masitinib dose was chosen based on pre-
clinical data (unpublished) and accumulated clin-
ical experience for masitinib in non-oncology
indications (10–14). Dose reduction or treatment
interruption was allowed for moderate or severe
toxicity according to predefined criteria. The study
protocol and amendments were approved by the
institutional review board or ethics committee at
each participating clinical site and was conducted
in accordance with the Declaration of Helsinki. All
patients provided written informed consent. This
trial was registered at www.clinicaltrials.gov as #
NCT02588677).
Protocol amendments were implemented dur-
ing the study with data remaining blinded through-
out, i.e. no changes were data-driven. There were
two key amendments: a non-premeditated passage
from a phase 2 to a demonstrative phase 2/3
design, requiring appropriate adjustment in sample
size and statistical hypothesis (first amendment
dated 02 July 2013 following recruitment of 34/
394 (9%) patients, of which none had completed
the 48-week treatment period); and implementa-
tion of a prospectively tiered design based on
aggressiveness phenotype (third amendment dated
08 October 2014 following recruitment of 142/394
(36%) patients, of which 46/394 (12%) had com-
pleted the 48-week treatment period). This latter
amendment involved categorization of patients
according to Amyotrophic Lateral Sclerosis
Functional Rating Scale-Revised (ALSFRS-R)
progression rate (DFS) (15–18), calculated from
disease-onset to baseline with a dichotomizing cut-
off at 1.1 points/month. Accordingly, patients
receiving masitinib 4.5mg/kg/d with post-onset
DFS < 1.1 points/month (referred to hereafter as
“Normal Progressors” and comprising an esti-
mated 84% of the ALS population) were prede-
fined as the primary efficacy population. All
necessary information was available from patient
records, meaning no retrospective data-collection
was necessary, with stratification (minimization
algorithm) implemented for the remaining (64%)
patient recruitment to ensure balanced treatment-
arms. This prospectively defined two-tiered
approach defines a more homogenous target popu-
lation (primary analysis), reducing variability and
therefore sample size requirements, while concur-
rently permitting evaluation (secondary analysis) of
the broader, more heterogeneous population. The
rationale for this amendment (detailed in the
Supplementary Information, eDiscussion Section
A), assumed that heterogeneity in ALS disease
aggressiveness reflects differing disease mecha-
nisms, with dysregulated immunity being one
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possibly factor (19), leading to an unpredictable
and likely divergent treatment-effect across the
overall population. Furthermore, the right-skewed
(positive-skew) characteristic of DFS histogram
distributions was a common observation in clinical
practice (20). This indicates that while a majority
of patients fall within a fairly narrow range of post-
onset DFS (e.g. 0.1–1.1 points/month), more rap-
idly progressing patients present with a far wider
range and are therefore a greater source of DFS
heterogeneity between treatment-arms.
Patients
Eligible patients were aged 18–75 years with a
laboratory-supported probable, probable, or defin-
ite diagnosis of ALS (revised El Escorial criteria)
(21,22), had less than 36 months duration of dis-
ease from the first ALS symptom (i.e. any progres-
sive focal weakness or atrophy) and forced vital
capacity (FVC) of at least 60% at baseline.
Additionally, patients were receiving a stable dose
of riluzole (100mg/d) for at least 30 d prior to
baseline. Patients were ineligible if presenting with
gastrostomy, dementia, significant organ or system
dysfunction, cancer, or uncontrolled medical con-
dition that might interfere with trial results, and
previous treatment with any investigational agent
within 3 months prior to baseline.
Study measurements
The primary endpoint was decline in ALSFRS-R
from baseline to week-48 (DALSFRS-R), with
assessments performed at weeks 4, 8, 12, and
every 12 weeks thereafter. Missing data were
imputed via last observation carried forward
(LOCF) methodology for those patients discontin-
uing because of toxicity or lack of efficacy before
week 48. Several predefined sensitivity analyses
were performed to test robustness of the primary
analysis result, including full analysis dataset (non-
LOCF) imputation methods and variations on
LOCF via censoring on reason for discontinu-
ation. Additional sensitivity analyses included the
conservative techniques of multiple imputation,
jump-to-reference, and tipping-point analysis (see
Supplementary eDiscussion Section B for detailed
description).
Predefined secondary analyses included assess-
ment of the broader “Normal and Fast Progressor”
masitinib 4.5mg/kg/d cohort, and corresponding
DFS-tiered low-dose (masitinib 3.0mg/kg/d)
cohorts. Secondary endpoints included change from
baseline in ALS Assessment Questionnaire 40-item
(ALSAQ-40) score (23), FVC, overall survival
(OS), and time-to-event analysis (an endpoint
driven by both death and a fixed disease progres-
sion on the ALSFRS-R scale) (24,25), defined here
as a deterioration of 9 points from baseline or
death. Exploratory analysis included assessment in
cohorts with less severe symptoms at baseline.
Patients were monitored for safety or toxicity
until 28 d after discontinuing study drug. Adverse
events (AE) and laboratory values (hematology,
blood biochemistry, and urinalysis) were classified
and graded according to Common Terminology
Criteria for Adverse Events version 4 (Bethesda,
MD). Safety analysis was reported regardless of
causality, according to dose and patient cohort. An
independent Data Safety Monitoring Committee
monitored safety throughout the study.
Statistical analysis
Patients were randomized using a computerized
central randomization system and minimization
method according to the covariates (i.e. prognostic
factors) of site of onset (spinal versus bulbar),
ALSFRS-R score, age, geographical region, and
post-onset DFS (as per the aforementioned proto-
col amendment). In this manner, the difference
among treatment groups, with respect to prognos-
tic factors, was minimized (Table 1). The safety
dataset comprised all patients that received at least
one dose of study medication, while the efficacy
dataset also required patients to have received at
least one intake of study medication and have at
least one post-baseline efficacy assessment.
Consistent with common practice, any patient
dying after randomization had an ALSFRS-R score
of zero imputed. All main, sensitivity, and sub-
group analyses reported herein were pre-specified
in the study’s statistical analysis plan prior to
unblinding unless stated otherwise.
To detect a 3.3-point difference (standard devi-
ation of 7.5 points assumed) in DALSFRS-R
between masitinib and placebo (corresponding to
an approximate 30% improvement in the rate of
ALSFRS-R decline), with a two-sided 5% signifi-
cance level and a power of 80% in the Normal
Progressor population, a sample size of 300
patients (100 in each treatment-arm, incorporating
a 5% margin) was necessary. Likewise, for the
broader population analysis (i.e. Normal and Fast
Progressors), an estimated 381 patients (127 per
treatment-arm) were required to detect a 3.3-point
difference (standard deviation of 9.0 points
assumed). DALSFRS-R was calculated using a
model of analysis of covariance (ANCOVA),
adjusted on the aforementioned baseline covariates,
expressing results as difference of least-squares
means (DLSM) between treatments (masitinib ver-
sus placebo) with corresponding 95% two-sided
confidence intervals (CI) and statistical test p value
obtained via a re-randomization test (10,000 repli-
cate). Secondary endpoints were similarly analyzed
using ANCOVA or Kaplan–Meier methods.
One planned interim analysis was performed
(cutoff date 22 February 2016) after 50% of
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randomized patients could have reached the 48-
week timepoint. Consistent with predefined rules
and justified considering the urgent unmet medical
need in ALS, positive interim results led to an early
regulatory submission. Because the full study
population had been randomized prior to interim
readout it was recommended to continue the
blinded study without further amendment until final
readout, thereby providing fully developed evidence
and supportive follow-up analysis for the positive
Table 1. Baseline patient characteristics according to the ITT dataset (N¼394). Treatment-arms were well balanced for all
baseline parameters.














Gender (male) (n, %) 69 (60.5%) 69 (65.1%) 70 (63.6%) 80 (60.2%) 83 (63.8%) 81 (61.8%)
Age (years)
(Mean±SD)
55.4±10.5 54.8± 10.8 54.9±10.3 55.2± 10.6 55.5±10.6 55.7± 10.2
Age (range) 27.0 ; 75.0 24.0 ; 79.0 33.0 ; 75.0 27.0 ; 75.0 24.0 ; 79.0 33.0 ; 75.0
Site of onset
Spinal (n, %) 90 (78.9%) 85 (80.2%) 92 (83.6%) 109 (82.0%) 107 (82.3%) 110 (84.0%)
Bulbar (n, %) 24 (21.1%) 21 (19.8%) 18 (16.4%) 24 (18.0%) 23 (17.7%) 21 (16.0%)
BMI (median)
[18.5 BMI <25] 22.8 23.4 23.5 22.5 23.4 23.4
[25 BMI 35] 28.0 27.6 28.0 28.1 27.6 28.0
ALS diagnosisc
Definite (n, %) 66 (57.9%) 64 (60.4%) 60 (54.5%) 79 (59.4%) 76 (58.5%) 73 (55.7%)
Probable (n, %) 38 (33.3%) 33 (31.1%) 37 (33.6%) 43 (32.3%) 44 (33.8%) 43 (32.8%)
Probable, laboratory-supported (n, %) 10 (8.8%) 9 (8.5%) 13 (11.8%) 11 (8.3%) 10 (7.7%) 15 (11.5%)
Disease durationd
From diagnosis (months) (Mean±SD) 9.7±7.3 10.9± 8.7 10.7±7.6 9.1± 7.0 9.7±8.4 10.0± 7.4
From first symptom 19.5±8.4 21.6±8.9 20.7±8.0 18.1±8.6 19.2± 9.6 19.2± 8.2
Post-onset DFS
a“Normal Progressors” (n, %) 114 (100%) 106 (100%) 110 (100%) 114 (85.7%) 106 (81.5%) 110 (84.0%)
Mean±SD (points/month) 0.49±0.24 0.49±0.25 0.48±0.25 0.71±0.69 0.73±0.63 0.65±0.48
Range (points/month) 0.05 ; 1.07 0.03 ; 1.08 0.09 ; 1.07 0.05 ; 5.00 0.03 ; 3.69 0.09 ; 2.24
ALSFRS-R score
Mean±SD 39.3±4.6 38.3± 5.3 38.6±5.1 38.1± 5.5 37.5±5.5 37.4± 5.7
Range 27.0 ; 47.0 23.0 ; 47.0 23.0 ; 46.0 21.0 ; 47.0 23.0 ; 47.0 21.0 ; 46.0
FVC (% predicted)
Mean±SD 90.3±19.0 89.0± 16.5 88.1±18.9 89.2± 18.7 87.5±16.9 86.8± 18.7
Range 37.0 ; 136.0 60.0 ; 131.0 51.0 ; 149.0 37.0 ; 136.0 45.0 ; 131.0 51.0 ; 149.0
ALSAQ-40 score
Mean±SD 30.2±14.0 32.7± 15.2 33.0±16.1 33.0± 15.8 35.6±16.4 35.8± 17.4
Range 3.1 ; 70.6 6.3 ; 74.4 3.1 ; 68.1 3.1 ; 74.4 6.3 ; 78.1 3.1 ; 80.6
Region
Western Europe & N America 72 (63.2%) 61 (57.5%) 68 (61.8%) 86 (64.7%) 81 (62.3%) 84 (64.1%)
Eastern Europe 8 (7.0%) 8 (7.5%) 5 (4.5%) 8 (6.0%) 8 (6.2%) 5 (3.8%)
Latin America 34 (29.8%) 37 (34.9%) 37 (33.6%) 39 (29.3%) 41 (31.5%) 42 (32.1%)
Country
Spain 39 (34.2%) 38 (35.8%) 40 (36.4%) 51 (38.3%) 53 (40.8%) 51 (38.9%)
Argentina 33 (28.9%) 36 (34.0%) 36 (32.7%) 38 (28.6%) 40 (30.8%) 41 (31.3%)
Italy 26 (22.8%) 16 (15.1%) 22 (20.0%) 28 (21.1%) 21 (16.2%) 26 (19.8%)
Slovakia 6 (5.3%) 4 (3.8%) 3 (2.7%) 6 (4.5%) 4 (3.1%) 3 (2.3%)
Netherlands 3 (2.6%) 4 (3.8%) 2 (1.8%) 3 (2.3%) 4 (3.1%) 3 (2.3%)
Canada 4 (3.5%) 1 (0.9%) 3 (2.7%) 4 (3.0%) 1 (0.8%) 3 (2.3%)
Greece 2 (1.8%) 4 (3.8%) 2 (1.8%) 2 (1.5%) 4 (3.1%) 2 (1.5%)
Portugal 0 (0.0%) 2 (1.9%) 1 (0.9%) 0 (0.0%) 2 (1.5%) 1 (0.8%)
Mexico 1 (0.9%) 1 (0.9%) 1 (0.9%) 1 (0.8%) 1 (0.8%) 1 (0.8%)
a“Normal Progressor” dataset defined as patients with a post-onset DFS of less than 1.1 points/month.
b“Normal and Fast Progressor” dataset includes all patients, regardless of the post-onset DFS selection criterion. DFS¼ALSFRS-R
progression rate from disease-onset to baseline. ALSFRS-R¼Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised.
“Normal and Fast Progressor” dataset is closely matched to the Safety (SAF) population. PBO¼Placebo plus riluzole.
M4.5¼Masitinib 4.5mg/kg/day plus riluzole. M3.0¼Masitinib 3.0mg/kg/day plus riluzole. BMI: body mass index (kg/m2);
ALSAQ-40¼ALS Assessment Questionnaire 40-item.
cALS diagnosis according to revised El Escorial criteria.
dDisease duration calculated from the first ALS symptom (i.e. any progressive focal weakness or atrophy) to baseline, or from time of
diagnosis to baseline.
FVC: forced vital capacity; SD: standard deviation
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interim result. Consequently, all tests reported
herein are performed at a significance level of 5%.
Results
Patients
Between April 2013 and December 2015, a total of
394 patients underwent randomization from 34 sites
in 9 countries. Three patients were excluded for effi-
cacy analysis due to lack of post-baseline efficacy
assessment or no drug intake, yielding a dataset of
391 patients: 132, 131, and 128 patients in the pla-
cebo, masitinib 3.0mg/kg/d, and masitinib 4.5mg/
kg/d treatment-arms, respectively (Figure 1). The
primary efficacy population (i.e. “Normal
Progressors” receiving masitinib 4.5mg/kg/d versus
placebo) comprised 105 and 113 patients, respect-
ively, of which 99 and 102 patients were assessable
for the primary endpoint, as determined by prede-
fined data imputation rules (see Supplementary
eDiscussion Section B). The number of patients dis-
continuing during the 48-week treatment period
was about 34% in both treatment-arms.
Randomized patients were well-balanced between
treatment-arms regarding proportion of patients
completing the 48-week treatment period (Figure 1)
and on all baseline parameters (including demo-
graphics, site of onset, disease duration, DFS, distri-
bution of slower progressive patients, baseline
scores, and geographical region) (Table 1 and
Supplementary eTable 2).
Primary efficacy analysis
For the primary efficacy population, DALSFRS-R
showed a significant benefit for masitinib over pla-
cebo with a between-group difference in
DALSFRS-R of 3.39 (9.24 versus 12.63); 95%
CI 0.65–6.13, p¼0.016 (Table 2 and
Supplementary eFigure 1). This represents a clin-
ically meaningful 27% slowing of ALSFRS-R
deterioration over the 48-week treatment period.
All predefined sensitivity analyses on the pri-
mary endpoint were statistically significant (see
Supplementary eDiscussion Section B and
eTable 3). Considering the most pessimistic full
analysis dataset (imputation with penalty), which
estimates progression for similarly clustered
patients then imputes missing values using this
average trend, DALSFRS-R for masitinib (n¼104)
was 11.4 versus 14.4 for placebo (n¼111);
corresponding to a DLSM of 3.0 and significant
26% slowing in rate of decline (p¼ 0.018).
Additional sensitivity analyses were performed
using the recommended techniques of multiple
imputation, jump-to-reference, and tipping-point.
Results from these analyses were all significant
(p¼0.048, p¼ 0.039, and a 77% penalty, respect-
ively) and convergent with the positive primary
analysis outcome (see Supplementary eDiscussion
Section B). Considering the FCS-REGPMM (Fully
Conditional Specification Regression Predictive
Mean Matching) method, modeled on factors hav-
ing maximum impact on variability of ALSFRS,
DLSM was 3.4 (95% CI 0.53–6.33; p¼ 0.020).
Secondary efficacy analyses
Significance on DALSFRS-R was not reached for
the secondary analysis populations of the “Normal
and Fast Progressor” masitinib 4.5mg/kg/d cohort
(which showed a DLSM of 2.09 in favor of masiti-
nib, p¼ 0.12), or either of the low-dose (masitinib
3.0mg/kg/d) cohorts (Supplementary eTable 4).
The observed significant treatment-effect for
“Normal Progressors” receiving masitinib 4.5 mg/
kg/d (primary efficacy population) was however sup-
ported by positive benefit in various secondary end-
points (Table 2 and Supplementary eFigure 1).
Patients on masitinib showed a significantly lower
deterioration in quality-of-life, as measured by the
ALSAQ-40 scale, with a between-group difference
of 29% (DLSM change of 19.42 versus 27.18;
p¼0.008). For respiratory function, as measured
by FVC, patients on masitinib showed a signifi-
cantly lower deterioration with a between-group
difference of 22% (DLSM change of 26.45
versus33.99; p¼ 0.03). Time-to-event analysis
showed patients on masitinib had a significant 25%
delay in disease progression (20 versus 16 months,
p¼0.016) (Supplementary eFigure 2). Conversely,
there was no discernible difference in overall sur-
vival (OS) with median OS not being reached in
either the masitinib (4.5mg/kg/d) or placebo treat-
ment-arms.
Subgroup analysis
Subgroup analyses explored whether patient response
to masitinib was influenced by baseline disease sever-
ity, as determined by ALSFRS-R individual compo-
nent scores, e.g. exclusion of patients with zero-
point ALSFRS-R items at randomization. Results
showed that initiation of masitinib (4.5mg/kg/d) at
a less severe stage of disease produced greater treat-
ment-effect according to DALSFRS-R and time-to-
event analysis. This included a significant benefit in
the broader “Normal and Fast Progressor” cohort
(Supplementary eDiscussion Section C).
Safety
A summary of safety results during the 48-week
treatment period, regardless of causality, is pre-
sented in Table 3. Generally, patients receiving
masitinib at 4.5mg/kg/d (M4.5) reported higher
rates of AE, severe AE and serious AE than
patients receiving masitinib at 3.0mg/kg/d (M3.0)
or placebo, which were similar. Considering the
overall safety dataset (n¼ 393), rates of
Masitinib for the treatment of amyotrophic lateral sclerosis 9
discontinuation resulting from AE were 16.3, 16.0,
and 9.0% in the M4.5 (n¼ 129), M3.0 (n¼131),
and placebo (n¼133) treatment-arms, respect-
ively. Among 33 patients who died while on-treat-
ment or 28 d after discontinuing treatment, 10
(8%), 11 (8%), and 12 (9%) were from the M4.5,
M3.0, and placebo treatment-arms, respectively
(Table 3). No death was related to
study treatment.
Rates of AE (any grade) were 88% with M4.5,
85% with M3.0, and 79% with placebo. The only
AEs occurring at least 5% more frequently for
masitinib (regardless of dose) compared with
placebo were maculopapular rash and peripheral
edema (Table 4). Overall rates of serious AE were
31% with M4.5, 23% with M3.0, and 18% with
placebo. Overall rates of severe AE (grade 3/4)
were 29% with M4.5, 22% with M3.0, and 17%
with placebo. One isolated case (0.8%) of auto-
immune-like hepatitis was reported in the M4.5
treatment-arm, with the patient showing increased
liver transaminase levels (grade 3) at week-24 (26).
This resolved after masitinib was discontinued and
a combination of prednisone and azathioprine was
started. Three other cases of increased transami-
nases were reported (2 patients on M4.5 and 1
Figure 1. Patient flow diagram, detailing patient disposition for the ITT, assessable safety, assessable efficacy, primary efficacy, and
secondary efficacy populations. Primary efficacy population prospectively defined as “Normal Progressor” patients (pts) receiving
masitinib at 4.5mg/kg/d versus placebo. “Normal Progressor” dataset defined as patients with a post-onset DFS of less than 1.1 points/
month. DFS¼ALSFRS-R progression rate from disease-onset to baseline. ALSFRS-R¼Amyotrophic Lateral Sclerosis Functional
Rating Scale-Revised. ITT¼ intention-to-treat population. PBO¼Placebo plus riluzole. M4.5¼Masitinib 4.5mg/kg/d plus riluzole.
M3.0¼Masitinib 3.0mg/kg/d plus riluzole. Secondary efficacy populations include the “Normal and Fast Progressor” masitinib 4.5mg/
kg/d cohort and DFS-tiered low-dose (masitinib 3.0mg/kg/d) cohorts. “Normal and Fast Progressor” dataset includes all patients,
regardless of the post-onset DFS selection criterion. FP ¼ “Fast Progressor” patients (defined as post-onset DFS 1.1 points/month).
†Primary endpoint¼ change in ALSFRS-R from baseline to week-48. Assessable patients for primary endpoint according to rule 1 for
missing data imputation, i.e. last observation carried forward methodology for those patients discontinuing because of toxicity or lack of
efficacy before week 48 (see Supplementary eDiscussion B for detailed description of rules).
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patient on M3.0), all of which were non-severe
cases that resolved without sequelae following tem-
porary treatment interruption or premature discon-
tinuation as per protocol safety rules.
Discussion
While patients receiving masitinib at 4.5mg/kg/d
as an add-on therapy to riluzole experienced more
frequent SAE and severe AE with respect to pla-
cebo, no distinct event contributed to these higher
rates (see Supplementary eTables 6 and 7, respect-
ively). No new safety concerns were identified for
masitinib, findings being consistent with masiti-
nib’s known risk profile (12–14). Masitinib showed
significant benefit in DALSFRS-R over placebo for
the study’s predefined primary efficacy population,
exceeding the clinically meaningful target of slowing
ALSFRS-R decline by 20% (27). Exploratory sub-
group analyses indicated further improvement is
possible when initiating treatment at a less severe
stage of disease (e.g. exclusion of patients with zero-
point ALSFRS-R items at baseline). Secondary end-
points also showed significant improvement in terms
of quality-of-life (ALSAQ40), respiratory function
(FVC), and time-delay in ALSFRS-R deterioration
or death (time-to-event analysis).
An innovative feature of this study design was
the use of DFS to ensure a more homogeneous pri-
mary efficacy population, thereby potentially miti-
gating the risk of divergent treatment-effect across
the overall population and reducing required
Table 2. Results summary for the primary efficacy population of “Normal Progressor” patients receiving masitinib 4.5mg/kg/d
versus placebo.
nd LSM DLSM [95% CI] p Value
aALSFRS-R
PBO 102 12.6 3.4 [0.7 ; 6.1] 0.016e
M4.5 99 9.2
bALSAQ-40
PBO 102 27.2 7.8 [13.5 ; -2.1] 0.008
M4.5 99 19.4
bFVC
PBO 102 34.0 7.5 [0.8 ; 14.3] 0.03
M4.5 98 26.5
b,cTIME-TO-EVENT – – Median [95% CI] p Value
PBO 113 – 16 months [11;19] 0.016
M4.5 105 – 20 months [14;30]
“Normal Progressor” dataset defined as post-onset DFS <1.1 points/month. DFS¼ALSFRS-R progression rate from disease-onset.
ALSFRS-R¼Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised.
aPrimary endpoint.
bSecondary endpoint.
cTime-to-event analysis defined as time interval (months) for ALSFRS-R deterioration of 9 points from baseline or death.
dThe primary efficacy population (“Normal Progressors” receiving masitinib 4.5mg/kg/d versus placebo) comprised 105 and 113
patients, respectively, of which 99 and 102 patients were assessable for the primary endpoint, as determined by the predefined rule 1
for missing data imputation (see Supplementary eDiscussion Section B for detailed description of rules).
ep Value obtained via a re-randomization test. LSM¼Least-squares means difference from baseline. DLSM¼Between treatment-arm
difference of LSM. 95% two-sided confidence intervals [95% CI]. PBO¼Placebo plus riluzole. M4.5¼Masitinib 4.5mg/kg/d plus
riluzole. ALSAQ-40¼ALS Assessment Questionnaire. FVC: forced vital capacity
Table 3. Safety summary over the 48-week treatment period according to dose and patient cohort (safety dataset, regardless
of causality)a.
Number (%) of patients with at least one PBO (n5 133) M4.5 (n5 129) D[M4.5] (%) M3.0 (n5 131) D[M3.0] (%)
AE (any grade) 105 (78.9%) 114 (88.4%) 9.4 111 (84.7%) 5.8
Severe AE (grade 3/4) 22 (16.5%) 38 (29.5%) 12.9 29 (22.1%) 5.6
Non-fatal serious AE 24 (18.0%) 40 (31.0%) 13.0 30 (22.9%) 4.9
AE leading to deathb 12 (9.0%) 10 (7.8%) 1.3 11 (8.4%) 0.6
AE leading to permanent discontinuationc 12 (9.0%) 21 (16.3%) 7.3 21 (16.0%) 7.0
AE leading to temporarily interruption 2 (1.5%) 16 (12.4%) 10.9 3 (2.3%) 0.8
AE leading to dose reduction 14 (10.5%) 43 (33.3%) 22.8 23 (17.6%) 7.0
aAdverse events (AE) were recorded until 28 d after treatment interruption with any AE not resolved at the death of the patients
recorded as an AE leading to death. Safety dataset excluded 1 patient from ITT because of no intake of study drug. PBO¼Placebo
plus riluzole. M4.5¼Masitinib 4.5mg/kg/day plus riluzole. D[M4.5] ¼ difference between M4.5 and placebo treatment-arms (M4.5
minus PBO). M3.0¼Masitinib 3.0mg/kg/d plus riluzole. D[M3.0] ¼ difference between M3.0 and placebo treatment-arms (M3.0
minus PBO).
bNo deaths were considered related to study treatment (masitinib or riluzole).
cAE leading to permanent discontinuation excluding death.
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sample size. Sensitivity analyses showed that the
dichotomizing cutoff of 1.1 points/month was well-
judged and associated with a sizeable “buffer
zone” for maintained significant treatment-effect
(see Supplementary eDiscussion Section A). This
highlights that it is the action of dichotomization
itself, and subsequent improved sample homogen-
eity, that is of key importance and not optimiza-
tion of a specific cutoff value.
One possible issue for interpretation of results
was the use of LOCF methodology in the primary
analysis. This concern was mitigated through
numerous and diverse sensitivity analyses, which
together corroborate the robustness of the primary
analysis and provide reassurance that the observed
treatment-effect was not driven by possible LOCF
bias (see Supplementary eDiscussion Section B).
Protocol amendments made during the study also
represent a challenge for interpretation of results;
in particular the transition to phase 2/3, albeit that
this change occurred with data remaining blinded
and prior to any of the patients having reached the
48-week timepoint.
The reduced treatment-effect observed in the
“Normal and Fast Progressor” cohort possibly
indicates that “Fast Progressors” (i.e. post-onset
DFS 1.1 points/month) are less susceptible to
masitinib at the doses tested. One speculative
explanation could be that these patients are experi-
encing a more aggressive form of ALS with rapid
loss of motor neurons requiring earlier interven-
tion. Additional disease mechanisms offer another
explanation for relative lack of efficacy in “Fast
Progressor” patients, with targeted therapies
expected to work on only a subset of ALS patients.
Indeed, gene expression profiling and proteomic
studies in ALS have successfully differentiated
patients with rapid and non-rapid progressive dis-
ease (the latter defined as having an equivalent
DFS of around 1.0 point/month) (19,28–31), such
evidence supporting the premise that these groups
represent pathophysiologically distinct forms
of ALS.
Finally, the reduced treatment-effect observed
for low-dose cohorts suggests dose-dependency,
with the starting dose of 3.0mg/kg/d being too low
to show significant improvement in DALSFRS-R
over placebo at the current sample size (p value
was 0.0661). This suggests that patients could pos-
sibly benefit from receiving a higher masitinib
Table 4. Most frequent adverse events for masitinib treatment relative to placebo over the 48-week treatment period according to







(n5 129) (%) D[M4.5] (%)
M3.0
(n5 131) (%) D[M3.0] (%)
MALL
(n5 260) (%) D[MALL] (%)
Rash maculo papular 1 (0.8) 11 (8.5) 7.7 6 (4.6) 3.8 17 (6.5) 5.8
Nausea 6 (4.5) 15 (11.6) 7.1 8 (6.1) 1.6 23 (8.8) 4.3
Respiratory failure 5 (3.8) 13 (10.1) 6.3 9 (6.9) 3.1 22 (8.5) 4.7
Edema peripheral 1 (0.8) 9 (7.0) 6.2 7 (5.3) 4.5 16 (6.2) 5.4
Iron deficiency anemia 2 (1.5) 9 (7.0) 5.5 3 (2.3) 0.8 12 (4.6) 3.1
Dyspnoea 3 (2.3) 10 (7.8) 5.5 3 (2.3) 0.0 13 (5.0) 2.7
Anxiety 1 (0.8) 8 (6.2) 5.4 5 (3.8) 3.0 13 (5.0) 4.2
Weight decreased
(loss)
9 (6.8) 14 (10.9) 4.1 13 (9.9) 3.1 27 (10.4) 3.6
Dyspepsia (indigestion) 4 (3.0) 9 (7.0) 4.0 3 (2.3) 0.7 12 (4.6) 1.6
Diarrhea 5 (3.8) 10 (7.8) 4.0 11 (8.4) 4.6 21 (8.1) 4.3
Fall 7 (5.3) 12 (9.3) 4.0 9 (6.9) 1.6 21 (8.1) 2.8
Abdominal pain upper 3 (2.3) 8 (6.2) 3.9 4 (3.1) 0.8 12 (4.6) 2.4
Blood bilirubin
increased
1 (0.8) 6 (4.7) 3.9 0 (0.0) 0.8 6 (2.3) 1.6
Rash 6 (4.5) 10 (7.8) 3.3 3 (2.3) 2.2 13 (5.0) 0.5
Constipation 2 (1.5) 6 (4.7) 3.2 2 (1.5) 0.0 8 (3.1) 1.6
Cystitis bacterial 2 (1.5) 6 (4.7) 3.2 3 (2.3) 0.8 9 (3.5) 2.0
Urinary tract infection 2 (1.5) 6 (4.7) 3.2 5 (3.8) 2.3 11 (4.2) 2.7
Eyelid edema 0 (0.0) 4 (3.1) 3.1 0 (0.0) 0.0 4 (1.5) 1.5
Upper respiratory tract
infection
1 (0.8) 5 (3.9) 3.1 2 (1.5) 0.7 7 (2.7) 1.9
Cough 3 (2.3) 7 (5.4) 3.1 0 (0.0) 2.3 7 (2.7) 0.4
Rash generalized 0 (0.0) 4 (3.1) 3.1 1 (0.8) 0.8 5 (1.9) 1.9
aAdverse events (AE) listed in order of greatest positive difference between M4.5 and placebo treatment-arms (M4.5 minus PBO).
AEs described using MedDRA preferred terms. Any given AE can be listed under multiple MedDRA preferred terms, which are not
therefore cumulative. Safety dataset excluded 1 patient from ITT because of no intake of study drug. PBO¼Placebo plus riluzole.
M4.5¼Masitinib 4.5mg/kg/d plus riluzole. D[M4.5] ¼ difference between M4.5 and placebo treatment-arms (M4.5 minus PBO).
M3.0¼Masitinib 3.0mg/kg/day plus riluzole. D[M3.0] ¼ difference between M3.0 and placebo treatment-arms (M3.0 minus PBO).
MALL ¼ pooled M4.5 and M3.0. D[MALL] ¼ difference between MALL and placebo arm (MALL minus PBO). AEs were recorded
until 28 d after treatment interruption.
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dose, any risk of increased toxicities being mitigated
via implementation of a dose-escalation scheme as
previously described in the literature (14).
In conclusion, study AB10015 represents the
first successful randomized, controlled, phase 2/3
trial in ALS of a tyrosine kinase inhibitor. Results
show that masitinib at 4.5mg/kg/d can benefit
patients with ALS. A confirmatory phase 3 study
will be initiated to confirm these findings.
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